Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.

@article{Tang2010InfluenceOA,
  title={Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.},
  author={Patricia A. Tang and Gregory R. Pond and Eric Chen},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 1},
  pages={19-26}
}
BACKGROUND Our objective was to determine the variability in assessment between investigators (INV) and independent review committees (IRC) for response rate (RR) and progression-free survival (PFS). METHODS Phase III trials reporting INV and IRC assessments were identified. The difference in end point assessment (IRC - INV) across all study arms was determined. A random-effects model was used to calculate the mean difference between INV and IRC RR as well as PFS. Differences in estimated… CONTINUE READING
7 Extracted Citations
45 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-7 of 7 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 45 references

Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial

  • CN Sternberg, D Petrylak, F Witjes
  • J Clin Oncol (Meeting Abstracts)
  • 2007
Highly Influential
7 Excerpts

XELOX vs FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer

  • J Cassidy, S Clarke, E Diaz-Rubio
  • Gastrointestinal Cancers Symposium,
  • 2007
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…